Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Clin Exp Dermatol ; 44(5): e189-e192, 2019 Jul.
Article in English | MEDLINE | ID: mdl-30251264

ABSTRACT

In this case series, we retrospectively identified all patients treated with topical sodium thiosulfate (TST) for calcinosis cutis (CC) associated with underlying autoimmune connective tissue diseases at Mayo Clinic (Rochester, MN, USA) during the period 1 January 2012 to 27 June 2017. Of 28 patients identified (mean age 57.0 years; 96% female), 19 (68%) had clinical improvement of their CC with TST, 7 (25%) had no response and 2 (7%) had unknown response. There were adverse events in three patients: two had skin irritation and the third, who had a zinc allergy, experienced pain with application. Overall, our findings support those of previous case reports that TST appears to be a relatively well-tolerated adjuvant treatment for CC, although future studies with a control group are warranted to assess the true efficacy of TST for the indication of CC.


Subject(s)
Autoimmune Diseases/complications , Calcinosis/drug therapy , Chelating Agents/therapeutic use , Connective Tissue Diseases/complications , Skin Diseases, Metabolic/drug therapy , Thiosulfates/therapeutic use , Administration, Cutaneous , Adolescent , Adult , Aged , Aged, 80 and over , Arthritis, Juvenile/complications , Arthritis, Rheumatoid/complications , Calcinosis/complications , Dermatomyositis/complications , Female , Humans , Lupus Erythematosus, Systemic/complications , Male , Middle Aged , Retrospective Studies , Scleroderma, Systemic/complications , Skin Diseases, Metabolic/complications , Undifferentiated Connective Tissue Diseases/complications , Young Adult
2.
J Nat Med ; 71(1): 59-67, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27592007

ABSTRACT

Obesity results from excessive energy intake and physical inactivity, and predisposes one to various diseases. One of these reasons is that enlargement of adipocytes raises the lipid metabolic abnormalities that affect various organs. The skin is one such organ, and it has been reported that subcutaneous adipocyte cells secrete various factors and these factors are involved in reduction of dermal collagen fibers and fragility of the skin in obesity. The present study explored the efficacy of Kaempferia parviflora (KP) in preventing obesity-induced dermatopathy. We used Tsumura Suzuki obese diabetes (TSOD) mice as an obesity model. TSOD mice were fed a standard diet (MF) mixed with either an ethanol extract from KP (KPE), polymethoxyflavonoid-rich extract from KP (PMF), or polymethoxyflavonoid-poor extract from KP (X). We then evaluated the effect of these three KP fractions on aging-like skin damage induced by UVB irradiation. KPE and PMF caused a significant decrease of mouse body weight, and suppressed the increase in the thickness of the subcutaneous fat layer. In addition, KPE shifted the frequency of subcutaneous adipocyte sizes towards smaller cells possibly via its polypharmacological actions. Scanning electron microscopy revealed that the stereostructure of the collagenous fibers in the dermis was better retained in the KPE and PMF groups, in that order. These results offer the first evidence that KPE can attenuate obesity-induced dermatopathy more effectively than PMF, suggesting that KPE (or KP) might be a candidate supplement for preventing obesity-related skin disorders.


Subject(s)
Obesity/complications , Plant Extracts/pharmacology , Real-Time Polymerase Chain Reaction/methods , Skin Diseases, Metabolic/drug therapy , Zingiberaceae/chemistry , Animals , Disease Models, Animal , Male , Mice , Mice, Obese , Skin Diseases, Metabolic/etiology
3.
Clin Exp Dermatol ; 41(3): 275-8, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26290127

ABSTRACT

Calciphylaxis is characterized by abnormal calcification of vessels and skin; however, its aetiology and pathogenesis remain unclear. Entities frequently associated with calciphylaxis are end-stage renal disease, diabetes mellitus, hypercalcaemia, hyperphosphataemia, elevated calcium-phosphate product, hyperparathyroidism and possible hypercoagulable states. Skin lesions may remain quiescent or may develop suddenly and progress rapidly. They are more common on the legs. Treatment of calciphylaxis is very challenging and requires interdisciplinary management. We present a case that highlights the difficulty of treating calciphylaxis. A multidisciplinary approach was vital for the proper treatment of our patient. This case also demonstrates the importance of searching for underlying hypercoagulable states, especially in recalcitrant cases. In cases of calciphylaxis with vessel occlusion from microthrombi, heparin therapy would be a logical next step. The effect of anticoagulation may be rapid and impressive.


Subject(s)
Anticoagulants/therapeutic use , Calciphylaxis/drug therapy , Heparin/therapeutic use , Skin Diseases, Metabolic/drug therapy , Thrombophilia/drug therapy , Female , Humans , Leg , Middle Aged , Treatment Outcome
6.
J Vet Diagn Invest ; 24(4): 763-6, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22585959

ABSTRACT

In juvenile cattle, vitamin A deficiency is reported most commonly as a neurological condition; only rarely are there dermatologic manifestations. In the current study, alopecia, severe epidermal and follicular orthokeratosis, and acanthosis due to hypovitaminosis A are reported in 2 of 32 Angus calves, with a third animal suspected. Affected animals responded to vitamin A supplementation, and no additional calves displayed signs. Vitamin A acts on skin by regulating DNA transcription in keratinocytes, reducing the number of tonofilaments and desmosomes, both involved in cell-to-cell adhesion. Hence, adequate levels of dietary vitamin A are necessary for normal keratinocyte turnover, and deficiencies result in retention of keratinized cells (orthokeratosis). The present report reminds diagnosticians to consider vitamin A deficiency in cases of orthokeratotic dermatopathy in cattle.


Subject(s)
Cattle Diseases/metabolism , Skin Diseases, Metabolic/veterinary , Vitamin A Deficiency/veterinary , Animals , Biopsy/veterinary , Cattle , Fatal Outcome , Female , Histocytochemistry/veterinary , Skin Diseases, Metabolic/drug therapy , Vitamin A/therapeutic use , Vitamin A Deficiency/metabolism
8.
Hautarzt ; 61(12): 1063-71; quiz 1072, 2010 Dec.
Article in German | MEDLINE | ID: mdl-21103856

ABSTRACT

Calciphylaxis represents a dermatological emergency with a mortality of up to 80%. The disease is characterized by a triad of arteriolar medial calcification, thrombotic cutaneous ischemia and necrotic ulcerations. Recently several mechanisms of vascular calcification have been identified. This may led to preventive measures in the future. Early diagnosis is important to avoid complications such as sepsis. The dermatologist plays an important role in early diagnosis based on the recognition of clinical presentation and histopathology. Patients with end-stage renal disease are most commonly affected by calciphylaxis. The most frequent non-uremic predisposing conditions are primary hyperparathyroidism, malignancies, alcohol-induced liver disease, and autoimmune connective tissue diseases. Medical treatment aims to normalize mineral metabolism to reduce the serum concentration of sodium phosphate and thus to prevent precipitation and calcification. Newer compounds are bisphosphonates, non-sodium/non-aluminium phosphate binders, cinacalcet, paricalcitrol, and sodium thiosulfate. Among the surgical procedures parathyroidectomy did not result in a significant survival benefit. An aggressive surgical debridement of necrotic ulcerations, on the other hand, improved survival. Early diagnosis and a multidisciplinary treatment approach including re-vascularization by the vascular surgeon, repeated surgical debridement and split skin transplantation support wound healing and insure limb conservation.


Subject(s)
Calciphylaxis/diagnosis , Skin Diseases, Metabolic/diagnosis , Biopsy , Bone Density Conservation Agents/therapeutic use , Calciphylaxis/drug therapy , Calciphylaxis/etiology , Calciphylaxis/pathology , Chelating Agents/therapeutic use , Combined Modality Therapy , Debridement , Diagnosis, Differential , Diphosphonates/therapeutic use , Ergocalciferols/therapeutic use , Humans , Hyperparathyroidism/complications , Kidney Failure, Chronic/complications , Necrosis , Negative-Pressure Wound Therapy , Prognosis , Risk Factors , Skin/pathology , Skin Diseases, Metabolic/drug therapy , Skin Diseases, Metabolic/etiology , Skin Diseases, Metabolic/pathology , Thiosulfates/therapeutic use
9.
Am J Kidney Dis ; 42(3): E11-3, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12955705

ABSTRACT

The authors present a case of acquired reactive perforating collagenosis developed in a nondiabetic hemodialysis patient, who was treated successfully with allopurinol. Treatment of acquired reactive perforating collagenosis is difficult and often ineffective. The patient had been unresponsive to conventional treatments, but the pruritus was controlled, and skin lesions subsequently resolved after the treatment with allopurinol. Possible mechanisms of allopurinol treatment for acquired reactive perforating collagenosis are discussed.


Subject(s)
Allopurinol/therapeutic use , Collagen Diseases/etiology , Enzyme Inhibitors/therapeutic use , Renal Dialysis , Skin Diseases, Metabolic/etiology , Collagen Diseases/drug therapy , Humans , Male , Middle Aged , Pruritus/drug therapy , Pruritus/etiology , Skin Diseases, Metabolic/drug therapy
10.
Ann Rheum Dis ; 62(3): 267-9, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12594118

ABSTRACT

OBJECTIVES: To evaluate the effect of minocycline as treatment for cutaneous calcinosis in limited cutaneous systemic sclerosis (lcSSc). METHODS: Patients with lcSSc who had cutaneous calcinosis causing pain or ulceration, or both, were prescribed minocycline 50 or 100 mg daily regularly in an open label manner between November 1994 and April 2000. At routine clinical follow up the appearance of the calcinosis deposits was assessed clinically and radiographically, and the patients' assessment of the degree of discomfort, size, and frequency of ulceration was recorded. Demographic data, including disease duration, clinical features, and antinuclear antibody (ANA) titres, were also recorded. RESULTS: Nine patients have been treated to date. Eight of the nine patients were ANA positive, five of whom were positive for anticentromere antibodies. Eight patients have shown definite improvement and seven patients continue to receive treatment. The frequency of ulceration and inflammation associated with the calcinosis deposits decreased with treatment. The size of the calcinosis deposits also decreased but was less dramatic than expected. Improvement occurred at the earliest after one month of treatment with a mean (SD) of 4.8 (3.8) months. The mean (SD) length of treatment was 3.5 (1.9) years. An unexpected effect was the darkening of the calcinosis deposits to a blue/black colour. CONCLUSIONS: Minocycline may be effective in the control of calcinosis in systemic sclerosis. A low dose only is required and appears to be generally well tolerated. The mechanism of action may be mainly through inhibition of matrix metalloproteinases and anti-inflammatory effects. Calcium binding properties and antibacterial actions may also have a role.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Calcinosis/drug therapy , Minocycline/therapeutic use , Scleroderma, Systemic/complications , Skin Diseases, Metabolic/drug therapy , Adult , Aged , Aged, 80 and over , Antibodies, Antinuclear/analysis , Calcinosis/complications , Calcinosis/pathology , Female , Hand/pathology , Humans , Middle Aged , Scleroderma, Systemic/pathology , Skin Diseases, Metabolic/complications , Skin Diseases, Metabolic/pathology
13.
Ann Rheum Dis ; 57(4): 252-4, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9709184

ABSTRACT

OBJECTIVE: To establish whether diltiazem reduces subcutaneous calcinosis (SCC) in patients with systemic sclerosis (SSc), and whether this calcinosis is related to other signs or symptoms. METHODS: 47 patients with SSc were evaluated and divided into two groups according to the presence or absence of SCC. RESULTS: Among the 12 patients with SCC who were treated with diltiazem and had sequential hand radiographs (differential time between the two radiographs: 7.8+/-4 years), there was a slight radiological improvement in three patients only. More patients with SCC had anticentromere antibodies than patients without (p = 0.003), fewer had anti-Scl 70 antibodies (p = 0.01), more had telangiectasia and giant capillaries ( p + 0.04 and 0.048 respectively), and SCC patients had significantly fewer capillaries at the nailfold (p = 0.03). CONCLUSION: These results do not clearly indicate that diltiazem is effective in calcinosis associated with SSc. Among the patients with SSc, those who also had SCC exhibited a distinctive autoimmune profile and more severe cutaneous capillary injury than those without SCC.


Subject(s)
Calcinosis/complications , Calcium Channel Blockers/therapeutic use , Diltiazem/therapeutic use , Scleroderma, Systemic/complications , Skin Diseases, Metabolic/complications , Autoantibodies/blood , Calcinosis/drug therapy , Calcinosis/pathology , Capillaries/pathology , Centromere , DNA Topoisomerases, Type I , Female , Humans , Male , Middle Aged , Nuclear Proteins/immunology , Retrospective Studies , Scleroderma, Systemic/drug therapy , Scleroderma, Systemic/immunology , Skin/blood supply , Skin Diseases, Metabolic/drug therapy , Skin Diseases, Metabolic/pathology , Treatment Failure
SELECTION OF CITATIONS
SEARCH DETAIL
...